Practice Management News

Pharmaceutical companies Biogen and Eisai announced results from a phase 3 trial that demonstrated treatment with lecanemab reduced cognitive decline by 27% after 18 months compared with placebo.

Biomind Labs Inc. announced it has received a Controlled Substances License and will begin an 8-month project to produce and evaluate novel hydrogel-forming microneedle arrays for transdermal delivery of therapeutic psychedelic compounds.

In older adults with treatment-resistant depression, bilateral theta burst stimulation was noninferior to standard bilateral repetitive transcranial magnetic stimulation in reducing symptoms, per a recently published study.

A biopharmaceutical company has announced positive interim data from the first two cohorts in an ongoing phase 2 clinical trial of its treatment for acute cannabinoid intoxication.

Multimorbidity was associated with a 63% increased risk for incident dementia, with the greatest risk linked to hypertension and diabetes, researchers reported in JAMA Network Open.

In individuals with major depressive disorder and childhood trauma, symptoms improved significantly following pharmacological and psychotherapeutic treatments, regardless of severity, per a study published in Lancet Psychiatry.

HHS has awarded more than $1.6 billion in investments for communities across the country to address the addiction and overdose crises.

Although it was well tolerated, the anti-amyloid antibody crenezumab did not reduce clinical decline in patients with Alzheimer's disease, researchers reported in JAMA Neurology.

Entrepreneurial opportunities for physicians are becoming more important than ever, according to a presenter at the Women in Medicine Summit.

A perceived lack of paternal support following a stillbirth increased mothers’ odds of developing depression or anxiety, according to a study published in JAMA Network Open.